Brenus Pharma
My visitor profile
Brenus Pharma
Description of your activity
- French clinical-stage biotech developing the Stimulated-Ghost-Cell (SGC) platform to address cancer's evolving challenges. SGC mimics cancer’s relapsing conditions, making tumor visible to the immune system, allowing it to target and destroy evolving tumor cells. This technology overcomes the limits of classical immunotherapies by training the immune system to recognize 250+ tumor-specific targets, including neoantigens. Brenus is launching its First in Human study in colorectal cancer.
More information
- We aim to engage with pharmaceutical companies to join forces for patient’s centric innovation. Following the successful closure of a $25M Series A funding round with French and Belgian investors, we are also ready to discuss a Series B anticipating our Phase II and to continue driving growth and innovation with our innovative SGC platform
Emerging company
Paul BRAVETTI
CEO
Date of your company creation:
- Between 3 & 5 years
Main sector
- Biotechnology - Therapeutics and Diagnostics
Address
- Country : FRANCE
- City : Lyon
- Zip Code : 69002
Participation objectives
Partnering objectives
- Out-licensing / collaboration opportunities, Financing / investment opportunities, Network development
Description of my participation objective
-
"CROSSED-VIEWS #2 : 10-YEAR VISION ON TREATMENT / IMMUNITY
10.30 / 11.00 (6/05)
The clinician’s perspective: J.Pierre Delord, CEO IUCT-Oncopole, Unicancer Vice President
The entrepreneur’s perspective: Paul Bravetti, CEO Brenus Pharma.